BPC-157 vs GHK-Cu Head-to-Head Efficacy: What the Evidence Actually Shows
HealthRX.com
No head-to-head human trial exists for these peptides
Key numbers
- 30 patientsPatients across 3 BPC-157 studies in a 2026 orthopaedic systematic review, rated very low certaintySource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 86 evaluable patientsEvaluable patients in the venous ulcer trial where a 0.4% GHK-Cu cream was no different from placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 91.6%Share of BPC-157-only knee pain patients reporting significant improvement in an uncontrolled chart reviewSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 10 mgTotal BPC-157 dose injected around the bladder wall in twelve women with interstitial cystitis, single armSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
From the public record
Registered clinical studies: BPC-157 and GHK-Cu
As of 2026-11-11, ClinicalTrials.gov lists 4 registered studies naming BPC-157 and 4 naming GHK-Cu as an intervention. 0 and 0 of them, in that order, are phase 3.
| Measure | Value |
|---|---|
| BPC-157: registered studies | 4 |
| GHK-Cu: registered studies | 4 |
| BPC-157: recruiting now | 1 |
| GHK-Cu: recruiting now | 1 |
| BPC-157: completed | 1 |
| GHK-Cu: completed | 1 |
| BPC-157: phase 3 studies | 0 |
| GHK-Cu: phase 3 studies | 0 |
How this was calculated
Searched the ClinicalTrials.gov intervention field for each name separately, downloaded every record and counted by status and phase.
Studies whose intervention field matches each name, any condition, all statuses; a study naming both is counted for each
Study counts show how much research is registered, not which drug works better or is safer. Older and more widely used drugs have more studies.
From the public record
Published papers: BPC-157 and GHK-Cu
PubMed indexes 225 papers that mention BPC-157 in the title or abstract and 93 that mention GHK-Cu. In 2025 the counts were 16 and 9.
| Measure | Value |
|---|---|
| BPC-157: papers, all years | 225 |
| GHK-Cu: papers, all years | 93 |
| BPC-157: papers, 2016 to 2025 | 110 |
| GHK-Cu: papers, 2016 to 2025 | 55 |
| BPC-157: papers in 2025 | 16 |
| GHK-Cu: papers in 2025 | 9 |
How this was calculated
Ran a PubMed title and abstract search for each name separately and recorded counts by publication year. No filtering by study type or quality.
PubMed records with each name in the title or abstract, all article types and species; a paper naming both counts for each
Paper counts show research attention, not which option works better. A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.
At a glance
- BPC-157 orthopaedic review / 3 studies, 30 patients, very low certainty [1]
- GHK-Cu human evidence / Small cream trials; one found no benefit over placebo [2][3]
- BPC-157 mechanism / Molecular targets not identified [5]
- GHK-Cu mechanism / Proposed from laboratory and animal work [6]
- FDA approval / Neither peptide [4][5]
- Sport / BPC-157 named on WADA's prohibited list; GHK-Cu not named [7]
- Compounding / BPC-157 in none of FDA's three interim categories; non-injectable GHK-Cu in category 1 [4]
What are BPC-157 and GHK-Cu?
BPC-157 is a synthetic peptide of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with a molecular weight of about 1419.5 g/mol, described as a fragment of a protein first isolated from human gastric juice [5]. Websites sell it as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use' [5].
GHK-Cu is the copper(II) complex of GHK, a tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva and urine, with levels reported to decline with age; GHK is proposed to work as a copper complex [6]. Skin-care serums and creams with copper peptide are sold as cosmetics without FDA approval. Whether a product is a cosmetic or a drug depends on its intended use, and claims to treat disease or change the body's structure or function make it a drug [8]. An injectable GHK-Cu product is not a cosmetic, and no FDA-approved drug is known to contain GHK-Cu [4][8].
GHK-Cu is a different compound from copper histidinate (Zycubo), which FDA approved on January 12, 2026 for Menkes disease in children [4][9].
How do the evidence sets compare?
BPC-157's human data come from knee-pain and bladder-pain reports and small safety pilots [10][11][12]. GHK-Cu's come from skin-care and ulcer trials [3][2].
| BPC-157 | GHK-Cu | |
|---|---|---|
| FDA-approved product | None [5] | None [4] |
| Human studies found | Orthopaedic/regenerative review: 3 studies, 30 patients, very low certainty [1] | Small randomized cream trials; one negative vs placebo [2][3] |
| Main proposed mechanism | Unknown; molecular targets not identified [5] | Copper-complex actions proposed from laboratory and animal work [6] |
| WADA status | Named in class S0, prohibited at all times [7] | Not named [7] |
Questions worth asking
What human evidence exists for BPC-157?
A 2026 systematic review searched through June 1, 2026 and found 3 studies with 30 patients total. All were of poor methodological quality, certainty of evidence was rated very low, and the reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [1].
Knee pain. A retrospective chart review at one Florida clinic covered 17 patients, 16 of whom were reached by phone. Twelve received intra-articular BPC-157 alone and 4 received it with thymosin beta-4; 11 of the 12 BPC-157-only patients (91.6%) reported significant improvement. There was no control group, no validated outcome tool, and results were recalled rather than measured [10].
Interstitial cystitis. Twelve women aged 39 to 76 who had not responded to pentosan polysulfate received a total of 10 mg of BPC-157 injected around the bladder wall in a single procedure. Ten reported complete symptom resolution and 2 reported about 80% improvement. Single arm, no placebo, patient-rated [11].
Intravenous safety. Two adults received 10 mg intravenously on day 1 and 20 mg on day 2, with no measurable change in tested heart, liver, kidney, thyroid or glucose markers and no side effects reported. With 2 people, the study cannot establish safety [12].
There is also an ulcerative colitis enema study that exists only as a meeting abstract. Per FDA, 53 people with mild to moderate disease were randomized to BPC-157 80 mg or placebo daily for 2 weeks. The abstract says it was well tolerated with no difference in adverse events versus placebo, but it has too little detail to judge effectiveness, and no full paper exists [5].
FDA also found no human studies of BPC-157 given by mouth, by subcutaneous injection, by nasal spray or on the skin [5].
What human evidence exists for GHK-Cu?
Two randomized human trials are the core of the record, and both are small.
After CO2 laser resurfacing. Thirteen patients completed a randomized trial of post-treatment skin care with or without GHK-Cu on circumoral skin resurfaced with a CO2 laser. Computer analysis and blinded evaluators found no significant difference in resolution of redness, wrinkles or overall skin quality; a patient questionnaire did show a significant difference in overall skin quality favoring GHK-Cu (P=.04) [3].
Venous stasis ulcers. In a prospective randomized evaluator-blinded trial with 86 evaluable patients, a 0.4% tripeptide copper complex cream was no different from an inert vehicle placebo for ulcer size. Silver sulfadiazine 1% did reduce ulcer size [2].
A 2026 systematic review of GHK-Cu, which searched 2005 to 2026 and kept 64 records, describes the human literature as thin and fragmented: most randomized trials are small and run on facial cosmetic creams, and microneedle delivery has not been tested in a single registered, adequately powered human randomized trial [13].
A narrative review by the researchers who proposed GHK's mechanisms reports cosmetic benefits (firmer skin, fewer fine lines) and effects on at least 4,000 human genes, but it summarizes laboratory and company-type data rather than a trial [6].
How do the proposed mechanisms differ?
BPC-157's mechanism in people is not established. FDA's July 2026 review says its molecular targets have not been identified, its mechanisms 'remain poorly understood', and dose-response relationships for the reported protective effects were not established; the protective effects themselves come from rat studies [5].
GHK-Cu's proposed actions come from laboratory and animal work summarized by the researchers who proposed them: stimulating collagen and proteoglycan production, modulating metalloproteinases and their inhibitors, attracting immune and endothelial cells to an injury, and accelerating wound healing in dogs, rats, mice and pigs [6]. These are proposed mechanisms, not proven human effects [6].
What safety information exists for each?
FDA searched its adverse-event database through December 4, 2025 and found 3 reports for BPC-157, all for injectable product: injection-site redness and swelling for 9 days in a patient who also used compounded thymosin; shortness of breath that led to an emergency room visit; and widespread darkening of the skin and gums that recurred when the patient was re-exposed to a BPC-157 plus TB-500 'research' product. FDA said it cannot tell whether BPC-157 caused these [5].
In 28-day intramuscular animal studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels. Longer studies and cancer-risk studies were not available [5]. FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [5].
For GHK-Cu, FDA's stated concern is specific to the injectable form: compounded injectable drugs containing GHK-Cu 'may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities', and there are 'limited data in humans to inform safety-related considerations' [14]. The abstracts of the two randomized cream trials give no adverse-event rates [2][3].
What is the regulatory status of each?
BPC-157 is not an FDA-approved drug. There is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [5]. It sits in none of the three interim categories FDA uses for bulk substances nominated for compounding, and category 1, the group FDA says it generally will not act against compounders for when its conditions are met, does not cover it [4][15]. BPC-157 was in category 2 (significant safety risks) from September 2023 until April 22, 2026, when it moved to the 'nominated but withdrawn' table after the nominators withdrew; that move was not a finding of safety [14].
On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against the recommendation of FDA staff. News reports give the vote as 8 to 6 with 1 abstention. Advisory committee recommendations are non-binding, BPC-157 is not on the list, and adding it requires formal rulemaking [16][18]. FDA's own reviewers had proposed that BPC-157 not be added, citing poor chemical characterization, limited safety and immunogenicity information, and insufficient evidence that it works for ulcerative colitis [5].
On October 28, 2026, HHS filed a notice announcing a draft enforcement-discretion policy covering six peptides including BPC-157. It says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide if conditions are met, such as BPC-157 acetate only, in subcutaneous, intramuscular, oral or topical forms, with a patient-specific prescription. It is a draft, does not establish rights, is not binding, and is not an approval [17][18]. WADA names BPC-157 in class S0, prohibited at all times [7].
For GHK-Cu, no FDA-approved drug contains it [4]. Non-injectable GHK-Cu is in category 1, the group FDA generally will not act against compounders for if the guidance's conditions are met [4][15]. Injectable GHK-Cu sits in FDA's 'nominated but withdrawn' table alongside the immunogenicity concern quoted above [14]. GHK-Cu is not among the six peptides in the HHS draft policy [18]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether to include GHK-Cu on the pharmacy bulks list, and no vote has happened [4]. GHK-Cu is not named on WADA's 2026 or 2027 Prohibited List, but class S0 covers substances with no approval from any governmental health authority, and the 2027 notes say peptides not specifically named may still be prohibited [7][19].
Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [17].
Topical copper peptide skin-care products, such as the copper peptide cream, are not FDA-approved drugs; cosmetics do not need FDA approval before sale [8].
Frequently asked questions
Which peptide has better evidence, BPC-157 or GHK-Cu?
Are BPC-157 or GHK-Cu FDA-approved?
Is BPC-157 prohibited in sport?
What doses were used in the human studies?
What is GHK-Cu in the body?
References
Show all 19 referencesHide references
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3).
- Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7.
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108.
- World Anti-Doping Agency.
- Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA.
- U.S. Food and Drug Administration.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13.
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17.
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24.
- Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- World Anti-Doping Agency.